Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200345577> ?p ?o ?g. }
- W4200345577 endingPage "77" @default.
- W4200345577 startingPage "77" @default.
- W4200345577 abstract "Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignancy that has the worst 5-year survival rate of all of the common malignant tumors. Surgery, chemotherapy, and/or chemoradiation remain the main tactics for PDAC treatment. The efficacy of chemotherapy is often compromised because of the substantial risk of severe toxicities. In our study, we focused on identification of polymorphisms in the genes involved in drug metabolism, DNA repair and replication that are associated with inter-individual differences in drug-induced toxicities. Using the microarray, we genotyped 12 polymorphisms in the DPYD, XPC, GSTP1, MTHFR, ERCC1, UGT1A1, and TYMS genes in 78 PDAC patients treated with FOLFIRINOX. It was found that the TYMS rs11280056 polymorphism (6 bp-deletion in TYMS 3'-UTR) predicted grade 1-2 neurotoxicity (p = 0.0072 and p = 0.0019, according to co-dominant (CDM) and recessive model (RM), respectively). It is the first report on the association between TYMS rs11280056 and peripheral neuropathy. We also found that PDAC patients carrying the GSTP1 rs1695 GG genotype had a decreased risk for grade 3-4 hematological toxicity as compared to those with the AA or AG genotypes (p = 0.032 and p = 0.014, CDM and RM, respectively). Due to relatively high p-values, we consider that the impact of GSTP1 rs1695 requires further investigation in a larger sample size." @default.
- W4200345577 created "2021-12-31" @default.
- W4200345577 creator A5013167188 @default.
- W4200345577 creator A5026610839 @default.
- W4200345577 creator A5035536780 @default.
- W4200345577 creator A5052939543 @default.
- W4200345577 creator A5059408969 @default.
- W4200345577 creator A5066629021 @default.
- W4200345577 creator A5084160279 @default.
- W4200345577 date "2021-12-29" @default.
- W4200345577 modified "2023-10-16" @default.
- W4200345577 title "TYMS 3′-UTR Polymorphism: A Novel Association with FOLFIRINOX-Induced Neurotoxicity in Pancreatic Cancer Patients" @default.
- W4200345577 cites W1975123165 @default.
- W4200345577 cites W1976523431 @default.
- W4200345577 cites W1978852093 @default.
- W4200345577 cites W1984328540 @default.
- W4200345577 cites W1993925721 @default.
- W4200345577 cites W1994177577 @default.
- W4200345577 cites W2001337137 @default.
- W4200345577 cites W2002291152 @default.
- W4200345577 cites W2002753352 @default.
- W4200345577 cites W2005228342 @default.
- W4200345577 cites W2012085610 @default.
- W4200345577 cites W2019587482 @default.
- W4200345577 cites W2020205310 @default.
- W4200345577 cites W2021410785 @default.
- W4200345577 cites W2023531107 @default.
- W4200345577 cites W2036706547 @default.
- W4200345577 cites W2041713873 @default.
- W4200345577 cites W2043543149 @default.
- W4200345577 cites W2045990148 @default.
- W4200345577 cites W2056042519 @default.
- W4200345577 cites W2060387717 @default.
- W4200345577 cites W2065829703 @default.
- W4200345577 cites W2066859729 @default.
- W4200345577 cites W2068694673 @default.
- W4200345577 cites W2070821144 @default.
- W4200345577 cites W2082562598 @default.
- W4200345577 cites W2085722748 @default.
- W4200345577 cites W2087826696 @default.
- W4200345577 cites W2097124161 @default.
- W4200345577 cites W2102265131 @default.
- W4200345577 cites W2102629607 @default.
- W4200345577 cites W2107262592 @default.
- W4200345577 cites W2115658806 @default.
- W4200345577 cites W2127449669 @default.
- W4200345577 cites W2129383450 @default.
- W4200345577 cites W2131276940 @default.
- W4200345577 cites W2131297071 @default.
- W4200345577 cites W2133969744 @default.
- W4200345577 cites W2138959625 @default.
- W4200345577 cites W2142603587 @default.
- W4200345577 cites W2145581547 @default.
- W4200345577 cites W2151253787 @default.
- W4200345577 cites W2152645308 @default.
- W4200345577 cites W2157004858 @default.
- W4200345577 cites W2164370613 @default.
- W4200345577 cites W2165715420 @default.
- W4200345577 cites W2221679707 @default.
- W4200345577 cites W2254509024 @default.
- W4200345577 cites W2322536880 @default.
- W4200345577 cites W2360224810 @default.
- W4200345577 cites W2530706879 @default.
- W4200345577 cites W2770862842 @default.
- W4200345577 cites W2777775302 @default.
- W4200345577 cites W2807081886 @default.
- W4200345577 cites W2882992725 @default.
- W4200345577 cites W2905708503 @default.
- W4200345577 cites W2980158468 @default.
- W4200345577 cites W2981290126 @default.
- W4200345577 cites W3046594723 @default.
- W4200345577 cites W3092435302 @default.
- W4200345577 cites W3146313979 @default.
- W4200345577 cites W4210976084 @default.
- W4200345577 cites W4211181525 @default.
- W4200345577 doi "https://doi.org/10.3390/pharmaceutics14010077" @default.
- W4200345577 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35056973" @default.
- W4200345577 hasPublicationYear "2021" @default.
- W4200345577 type Work @default.
- W4200345577 citedByCount "1" @default.
- W4200345577 countsByYear W42003455772022 @default.
- W4200345577 crossrefType "journal-article" @default.
- W4200345577 hasAuthorship W4200345577A5013167188 @default.
- W4200345577 hasAuthorship W4200345577A5026610839 @default.
- W4200345577 hasAuthorship W4200345577A5035536780 @default.
- W4200345577 hasAuthorship W4200345577A5052939543 @default.
- W4200345577 hasAuthorship W4200345577A5059408969 @default.
- W4200345577 hasAuthorship W4200345577A5066629021 @default.
- W4200345577 hasAuthorship W4200345577A5084160279 @default.
- W4200345577 hasBestOaLocation W42003455771 @default.
- W4200345577 hasConcept C104317684 @default.
- W4200345577 hasConcept C104451858 @default.
- W4200345577 hasConcept C121608353 @default.
- W4200345577 hasConcept C126322002 @default.
- W4200345577 hasConcept C134935766 @default.
- W4200345577 hasConcept C135763542 @default.
- W4200345577 hasConcept C143998085 @default.
- W4200345577 hasConcept C2776694085 @default.